Trial Search Results
Human Salivary Gland Disposition of Alda-341 in Patients Undergoing Salivary Gland Surgery
The purpose of this study is determine salivary gland disposition of d-limonene, the primary component in citrus peel and a common dietary supplement.
Salivary gland tissue and saliva will be collected to determine concentration of d-limonene and its metabolites in these tissues.
Stanford is currently not accepting patients for this trial.
- Drug: Alda-341
Early Phase 1
- Elected to undergo surgery for recent diagnosis of parotid or submandibular gland
- Ability to adhere to study visit schedule and other protocol requirements
- Operable candidate base on the surgeon's note
- Ability to understand and the willingness to sign a written informed consent document
- Nursing or pregnant
- Diagnosis of kidney disease, history of renal disease with creatinine > 1.5 mg/dL, or
currently on dialysis
- Diagnosis of end stage liver disease
- Any unstable medical condition
- Use of chemotherapy or radiotherapy within 4 weeks before first dose of study dietary
- Unwilling to stop dietary supplements 3 weeks before first dose of study dietary
Ages Eligible for Study
18 Years - 85 Years
Genders Eligible for Study